Larry Coffer
@larrycoffer.bsky.social
Breast Oncology Research Administrator
Just concluded a successful Advanced Breast Cancer Conference 2025! The two days were filled with powerful presentations, engaging panels, and most importantly, meaningful dialogue between patients and scientists. The personal stories shared and the thoughtful questions asked were truly inspiring.
March 2, 2025 at 5:55 PM
Just concluded a successful Advanced Breast Cancer Conference 2025! The two days were filled with powerful presentations, engaging panels, and most importantly, meaningful dialogue between patients and scientists. The personal stories shared and the thoughtful questions asked were truly inspiring.
HHMI kills program aimed at boosting inclusivity in STEM education | Science | AAAS www.science.org/content/arti...
HHMI kills program aimed at boosting inclusivity in STEM education
“Inclusive excellence” program had committed $60 million to 104 institutions
www.science.org
February 18, 2025 at 4:42 PM
HHMI kills program aimed at boosting inclusivity in STEM education | Science | AAAS www.science.org/content/arti...
Trump administration layoffs set to hit NIH are ‘devastating,’ former director Monica Bertagnolli says www.statnews.com/2025/02/16/n... via @statnews.com
Trump administration layoffs set to hit NIH are ‘devastating,’ former director Monica Bertagnolli says
Sweeping layoffs are set to hit federal health and science agencies, including at the NIH, and former director Monica Bertagnolli called the situation at the NIH “devastating.”
www.statnews.com
February 18, 2025 at 4:39 PM
Trump administration layoffs set to hit NIH are ‘devastating,’ former director Monica Bertagnolli says www.statnews.com/2025/02/16/n... via @statnews.com
Reposted by Larry Coffer
Vivienne Lucille Malone-Mayes (1932–1995) was the first African American full-time mathematics professor at Baylor University.
She studied properties of functions, as well as methods of teaching mathematics.
She was the fifth African American woman allowed to gain a PhD in mathematics in the US.
She studied properties of functions, as well as methods of teaching mathematics.
She was the fifth African American woman allowed to gain a PhD in mathematics in the US.
November 2, 2024 at 2:41 PM
Vivienne Lucille Malone-Mayes (1932–1995) was the first African American full-time mathematics professor at Baylor University.
She studied properties of functions, as well as methods of teaching mathematics.
She was the fifth African American woman allowed to gain a PhD in mathematics in the US.
She studied properties of functions, as well as methods of teaching mathematics.
She was the fifth African American woman allowed to gain a PhD in mathematics in the US.
Reposted by Larry Coffer
I can’t believe this. I was offline in an all day science meeting, and now this.
Universities LOSE money even w/ current fed indirect rates. They foot the bill for US science infrastructure.
This is how to kill the entire US research ecosystem.
grants.nih.gov/grants/guide...
Universities LOSE money even w/ current fed indirect rates. They foot the bill for US science infrastructure.
This is how to kill the entire US research ecosystem.
grants.nih.gov/grants/guide...
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
grants.nih.gov
February 8, 2025 at 5:30 AM
I can’t believe this. I was offline in an all day science meeting, and now this.
Universities LOSE money even w/ current fed indirect rates. They foot the bill for US science infrastructure.
This is how to kill the entire US research ecosystem.
grants.nih.gov/grants/guide...
Universities LOSE money even w/ current fed indirect rates. They foot the bill for US science infrastructure.
This is how to kill the entire US research ecosystem.
grants.nih.gov/grants/guide...
Reposted by Larry Coffer
Houston Nobel Prize nominee earns latest award for public health research: Dr. Peter Hotez, Congratulations! houston.innovationmap.com/peter-hotez-...
Houston Nobel Prize nominee earns latest award for public health research
Hotez and his team were selected to receive $500,000 from Lyda Hill Philanthropies to help fund The Texas Virosphere Project.
houston.innovationmap.com
February 7, 2025 at 5:50 PM
Houston Nobel Prize nominee earns latest award for public health research: Dr. Peter Hotez, Congratulations! houston.innovationmap.com/peter-hotez-...
Reposted by Larry Coffer
Are you passionate about staying on the cutting edge of advanced breast cancer care? Then mark your calendars for the Advanced Breast Cancer Symposium: Precision Medicine and Novel Therapeutics!
Register now: mdanderson.cloud-cme.com/course/cours...
Register now: mdanderson.cloud-cme.com/course/cours...
November 28, 2024 at 7:44 PM
Are you passionate about staying on the cutting edge of advanced breast cancer care? Then mark your calendars for the Advanced Breast Cancer Symposium: Precision Medicine and Novel Therapeutics!
Register now: mdanderson.cloud-cme.com/course/cours...
Register now: mdanderson.cloud-cme.com/course/cours...
📢 Proud to share that my department at @mdanderson.bsky.social has a strong presence at #SABCS this week! 🙌 Several colleagues are presenting their groundbreaking research on breast cancer. Looking forward to meeting many of you there! #SABCS #breastcancer #cancerresearch
December 10, 2024 at 8:21 PM
📢 Proud to share that my department at @mdanderson.bsky.social has a strong presence at #SABCS this week! 🙌 Several colleagues are presenting their groundbreaking research on breast cancer. Looking forward to meeting many of you there! #SABCS #breastcancer #cancerresearch
Reposted by Larry Coffer
The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! www.nature.com/articles/s41...
November 28, 2024 at 3:08 AM
The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! www.nature.com/articles/s41...
Reposted by Larry Coffer
Out in @TheLancetOncol
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer
PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group
@oncoalert.bsky.social
www.thelancet.com/journals/lan...
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer
PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group
@oncoalert.bsky.social
www.thelancet.com/journals/lan...
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006)...
These findings might suggest a potential advantage of nab-paclitaxel combined with
trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy
for patients with HER2-positive ...
www.thelancet.com
November 28, 2024 at 5:49 AM
Out in @TheLancetOncol
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer
PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group
@oncoalert.bsky.social
www.thelancet.com/journals/lan...
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer
PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group
@oncoalert.bsky.social
www.thelancet.com/journals/lan...
Reposted by Larry Coffer
Now out in ESMO_Open the NEOENDO translational study by @schettinif87.bsky.social & @prat-aleix-md.bsky.social team 🇪🇸 identifying predictors and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- BC
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
DEFINE_ME
www.esmoopen.com
November 28, 2024 at 6:48 PM
Now out in ESMO_Open the NEOENDO translational study by @schettinif87.bsky.social & @prat-aleix-md.bsky.social team 🇪🇸 identifying predictors and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- BC
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
Are you passionate about staying on the cutting edge of advanced breast cancer care? Then mark your calendars for the Advanced Breast Cancer Symposium: Precision Medicine and Novel Therapeutics!
Register now: mdanderson.cloud-cme.com/course/cours...
Register now: mdanderson.cloud-cme.com/course/cours...
November 28, 2024 at 7:44 PM
Are you passionate about staying on the cutting edge of advanced breast cancer care? Then mark your calendars for the Advanced Breast Cancer Symposium: Precision Medicine and Novel Therapeutics!
Register now: mdanderson.cloud-cme.com/course/cours...
Register now: mdanderson.cloud-cme.com/course/cours...
Reposted by Larry Coffer
We are looking forward to this year's San Antonio Breast Cancer Symposium which starts on December 10. Take a look at the full program for this important meeting featuring the latest research on breast cancer. sabcs.org/FullProgram #SABCS24 #breastcancer
November 27, 2024 at 6:12 PM
We are looking forward to this year's San Antonio Breast Cancer Symposium which starts on December 10. Take a look at the full program for this important meeting featuring the latest research on breast cancer. sabcs.org/FullProgram #SABCS24 #breastcancer